IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor).
JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Erscheinungsjahr: 2021
Publikationstyp: Zeitschriftenaufsatz
| Geprüft | Bibliothek |
Autoren
Ducreux, Michel (Autor)
Zhu, Andrew X. (Autor)
Cheng, Ann-Lii (Autor)
Galle, Peter R. (Autor)
Ikeda, Masafumi (Autor)
Nicholas, Alan (Autor)
Verret, Wendy (Autor)
Li, Lindong (Autor)
Gaillard, Vincent E. (Autor)
Lencioni, Riccardo (Autor)
Finn, Richard S. (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
